Skip to main content
Clinical Trials/EUCTR2020-004245-37-CZ
EUCTR2020-004245-37-CZ
Active, not recruiting
Phase 1

Randomised Placebo-Controlled Trial of Early Targeted Treatment of Patent Ductus Arteriosus with Paracetamol in Extremely Low Birth Weight Infants (ETAPA) - ETAPA

niversity College Dublin0 sites218 target enrollmentJanuary 10, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Patent Ductus Arteriosus
Sponsor
niversity College Dublin
Enrollment
218
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 10, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity College Dublin

Eligibility Criteria

Inclusion Criteria

  • \- They are inborn or transferred to a participating centre after birth and have a birth weight of \<1000g established by weight assessment on admission to NICU.
  • \- The treating doctors plan to offer them intensive care.
  • \- Large PDA is present on fnECHO, defined as PDA with diameter greater than 1\.5mm with non\-restrictive flow (defined as diastolic flow less than 50% of systolic flow), determined by targeted fnECHO between 6 and 12 hours of age.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 218
  • F.1\.2 Adults (18\-64 years) no
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- Infants with major congenital anomalies including neural tube defects, major structural cardiac anomalies (excluding PDA/ASD/PFO), abdominal wall defects and congenital diaphragmatic hernia and major dysmorphic features with an abnormal karyotype e.g. T21, T13, T18\.
  • \- The treating clinician does not intend to offer the infant intensive care.
  • \- Bidirectional shunt of PDA on ECHO (defined as shunt exceeding 30% of the right to left proportion of the shunting).
  • \- Grade II – IV IVH on point of care CRUSS on screening (between six to twelve hours of age).
  • \- PH prior to study commencement.
  • \- Severe PPHN.
  • \- History or examination suggestive of liver failure prior to study commencement.
  • \- Written informed consent has not been obtained before the infant is 12 hours of age, or the infant’s parent(s)/guardian(s) withdraw consent prior to commencement of the trial processes or assessments.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Research study for early treatment of Patent Ductus Arteriosus, placebo against paracetamol in extremely low birth weight infants (ETAPA)
EUCTR2020-004245-37-IEniversity College Dublin218
Completed
Not Applicable
A Randomized Placebo-controlled Trial of an Early Interventional Treatment with Mometasone Furoate Nasal Spray in Japanese Cedar/Cypress PollinosisJapanese cedar/cypress pollinosis
JPRN-UMIN000005985Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences50
Active, not recruiting
Phase 1
A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaReCOVID-19 InfectionMedDRA version: 20.0Level: LLTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2020-001449-38-GBChelsea and Westminster Hospital NHS Foundation Trust450
Not yet recruiting
Phase 2
Effect of Early initiation of breast milk fortificatioHealth Condition 1: P788- Other specified perinatal digestive system disorders
CTRI/2024/03/064394Post garduate institute of medical science and reaserch,Chandigarh
Not yet recruiting
Not Applicable
A Study of Lying Face Down to Help Improve Oxygen Levels of Adults Not Needing Ventilators in Intensive Care with COVID-19COVID-19SARS-CoV-2Respiratory - Other respiratory disorders / diseasesInfection - Other infectious diseases
ACTRN12620000740998Royal Prince Alfred Hospital20